<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0003-3170</journal-id>
<journal-title><![CDATA[Angiología]]></journal-title>
<abbrev-journal-title><![CDATA[Angiología]]></abbrev-journal-title>
<issn>0003-3170</issn>
<publisher>
<publisher-name><![CDATA[Arán Ediciones S.L.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0003-31702023000400008</article-id>
<article-id pub-id-type="doi">10.20960/angiologia.00503</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Flegmasia cerúlea dolorosa en paciente con trombocitopenia inmune primaria: un gran reto terapéutico]]></article-title>
<article-title xml:lang="en"><![CDATA[Phlegmasia cerulea dolorosa and primary immune thrombocytopenia: a therapeutic challenge]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez-Perdomo]]></surname>
<given-names><![CDATA[Luis Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romero-Mejía]]></surname>
<given-names><![CDATA[Edwin Alexis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domínguez-Ruiz]]></surname>
<given-names><![CDATA[Juan Diego]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Velasco-Hoyos]]></surname>
<given-names><![CDATA[María Fernanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-Covo]]></surname>
<given-names><![CDATA[Diego Armando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Surcolombiana Hospital Universitario Hernando Moncaleano Perdomo ]]></institution>
<addr-line><![CDATA[Neiva Huila]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2023</year>
</pub-date>
<volume>75</volume>
<numero>4</numero>
<fpage>264</fpage>
<lpage>267</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S0003-31702023000400008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S0003-31702023000400008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S0003-31702023000400008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: la flegmasia cerúlea dolorosa resulta de una trombosis venosa masiva aguda que provoca una obstrucción del drenaje venoso de una extremidad y se asocia con un alto grado de morbilidad.  Caso clínico: presentamos el caso de un paciente con flegmasia cerúlea dolorosa y múltiples factores de riesgo para desarrollarla, quien fue llevado a trombólisis dirigida por catéter, con lo que se logró salvar la extremidad.  Discusión: la flegmasia cerúlea dolorosa es una entidad poco frecuente que puede progresar de manera rápida y comprometer la vitalidad de la extremidad afectada o llevar a desenlaces fatales, por lo que requiere una pronta sospecha y una intervención emergente. La terapia antitrombótica sigue siendo el manejo de elección.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: phlegmasia cerulea dolorosa results from acute massive venous thrombosis that causes obstruction of the venous drainage of an extremity, and it's associated with a high morbidity.  Case report: we present the case of a patient with phlegmasia cerulea dolorosa and multiple risk factors for developing it, who was taken to catheter-directed thrombolysis successfully.  Discussion: phlegmasia cerulea dolorosathis is a rare entity that can progress rapidly and compromise the vitality of the limb or lead to fatal outcomes, which requires early suspicion and emergency intervention. Antithrombotic therapy continues to be the ideal treatment.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Flegmasia cerúlea dolorosa]]></kwd>
<kwd lng="es"><![CDATA[Trombólisis dirigida por catéter]]></kwd>
<kwd lng="es"><![CDATA[Anticoagulación]]></kwd>
<kwd lng="es"><![CDATA[Trombosis venosa profunda]]></kwd>
<kwd lng="en"><![CDATA[Phlegmasia cerulea dolorosa]]></kwd>
<kwd lng="en"><![CDATA[Catheterdirected thrombolysis]]></kwd>
<kwd lng="en"><![CDATA[Anticoagulation]]></kwd>
<kwd lng="en"><![CDATA[Deep vein thrombosis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarwar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Narra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Munir]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phlegmasia cerulea dolorosa]]></article-title>
<source><![CDATA[Tex Heart Inst J]]></source>
<year>2009</year>
<volume>36</volume>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mumoli]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Invernizzi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Luschi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phlegmasia cerulea dolorosa]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2012</year>
<volume>125</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1056-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maiti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phlegmasia cerulea dolorosa]]></article-title>
<source><![CDATA[Postgrad Med J]]></source>
<year>2016</year>
<volume>92</volume>
<numero>1093</numero>
<issue>1093</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phlegmasia Cerulea Dolens in the Upper Extremity: A Case Report and Literature Review]]></article-title>
<source><![CDATA[Ann Vasc Surg]]></source>
<year>2021</year>
<volume>76</volume>
<page-range>601.e7-11.e7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lippi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchís-Gomar]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Favaloro]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronavirus Disease 2019 - Associated Coagulopathy]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2021</year>
<volume>96</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>203-17</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghumman]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fatima]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of Thromboembolism with Eltrombopag: A Case Report of Deep Vein Thrombosis and Bilateral Pulmonary Embolism]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2023</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[YT]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[XF]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The incidence and risk factors for thrombosis in primary immune thrombocytopenia]]></article-title>
<source><![CDATA[Zhonghua Xue Ye Xue Za Zhi]]></source>
<year>2018</year>
<volume>39</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>942-6</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bidot]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jy]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Horstman]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiphospholipid anti- bodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2005</year>
<volume>128</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>366-72</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Dardik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis]]></article-title>
<source><![CDATA[Am J Surg]]></source>
<year>2006</year>
<volume>192</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>782-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaer]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Dayal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multimodal therapy for acute and chronic venous thrombotic and occlusive disease]]></article-title>
<source><![CDATA[Vasc Endovascular Surg]]></source>
<year>2005</year>
<volume>39</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>375-80</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haig]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Enden]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Grøtta]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial]]></article-title>
<source><![CDATA[Lancet Haematol]]></source>
<year>2016</year>
<volume>3</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e64-71</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vedantham]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Goldhaber]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
<name>
<surname><![CDATA[Julian]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2240-52</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Notten]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[de Smet André]]></surname>
<given-names><![CDATA[AEA]]></given-names>
</name>
<name>
<surname><![CDATA[Tick]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CAVA (Ultrasound-accelerated catheter-directed thrombolysis on preventing post-thrombotic syndrome) trial: Long-term follow-up results]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2021</year>
<volume>10</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
